DAFTAR PUSTAKA

1. Nasronuddin. HIV dan AIDS Pendekatan Biologi Molekuler, Klinis dan Sosial; 2012.

2. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Pedoman Nasional Pengendalian Tuberkulosis. 2014.

3. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Pedoman Diagnosis dan Penatalaksanaan Tuberkulosis di Indonesia; 2012.

4. Aditama TY. Tuberkulosis Diagnosis, Terapi dan Masalahnya; 2011.

5. Wood R, Lawn SD. Challenges facing LAM urine antigen test for diagnosing HIV associated tuberculosis. Expert Rev Mol Diagn. 2012; 12(6): p. 549-551.

6. Achkar JM, Lawn SD, Moosa MYS, Wright CA, Kasprowicz VO. Adjunctive Test for diagnosis of tuberculosis:serology, ELISPOT for site specific lymphocytes, urinary lipoarabinomannan, string test, and fine needle aspiration. The journal of infectious disease. 2011; 204: p. 130-141.

7. Crevel RV, Tom HM, Ottenhof, Van der Meer JWM. Innate immunity to mycobacterium tuberculosis. clinical microbiology reviews. 2002 April;: p. 294-309.

8. Fukuda T, Matsumura T, Ato M, Hamasaki M, Nishiuchi Y, Murakami Y. Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of Mycobacteria and pathogenesis of tuberculosis. MBIO. 2013; 4(1): p. 1-11.

9. Wood R, Racow K, Bekker LG, Middelkoop K, Vogt M, Kreiswirth BN, et al. Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. BMC Infectious Diseases. 2012; 12: p. 47.

10. Peter JG, Theron G, Dheda K. Can point-of-care urine LAM strip testing for tuberculosis add value to clinical decision making in hospitalised HIV-infected persons. PLOS ONE. 2012; 8(2).

11. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary

tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012; 12: p. 201-209.

12. Lawn SD, Churchyard G. Epidemiology of HIV associated tuberculosis running head : epidemiology of TB/HIV. Curr Opin HIV AIDS. 2009 July; 4(4): p. 325-333.

13. Wright G LS. Advances in the diagnosis of HIV associated tuberculosis. EMJ Respi. 2015; 3(1): p. 60-70.

14. Kementerian Kesehatan Republik Indonesia. Pedoman nasional pelayanan kedokteran tatalaksana tuberkulosis Jakarta; 2013.

15. Shrestha NK. Rapid diagnostic testing for mycobacterial infections. Future Microbiol. 2007; 2(4): p. 397-408.

16. International Standards Tuberculosis Care. ; 3.

17. Schuetz A, Haule A, Reither K, Ngwenyama N, Ranchow A, Meyerhans A, et al. Monitoring CD27 expression to evaluate mycobacterium tuberculosis activity ini HIV-1 infected individuals in vivo. PLOS ONE. 2011; 6(11).

18. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. Tuberculosis and HIV co-infection. PLOS Pathogens. 2012; 8(2): p. 1-7.

19. Ansari AW, Kamrulzaman A, Schmidt RE. Multifaceted impact of host C-C chemokine CCL2 in the immuno-pathogenesis of HIV-1/M tuberculosis co-infection. Frontier in immunology. 2013; 4(312): p. 1-7.

20. Jankute M, Grover S, Rana AK, Besra GS. Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets. Future microbiol. 2012; 7(1): p. 129-147.

21. Guirado E, Schlesinger LS, Kaplan G. Macrophages in tuberculosis : Friend or foe. Semin Immunopathol. 2011; 35(5): p. 563-583.

22. Hermayanti D. Respons imun dan pemeriksaan serologi pada tuberkulosis. 2011; 7(14).

23. Kartik K. Venkatesh, Swaminathan S, Andrews JR. Mayer KH. Tuberculosis and HIV co-infection screening and treatment strategies drugs. 2011; 71(9): p.

1133-1152.

24. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Immunology. 2011; 11: p. 343-354.

25. Kaur D, Henao AO, Pham H, Chatterjee D, Brennan PJ, Jackson M. Lipoarabinomannan of mycobacterium: mannose capping by a multifunctional terminal mannosyltransferase. PNAS. 2008; 46(105): p. 17973-17977.

26. Briken V, Porcelli SA, Besra GS, Kremer L. Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Molecular microbiology. 2004; 53(2): p. 391-403.

27. Morita YS, Patterson JH, Jacobe HB, McConville Mj. Biosynthesis of mycobacterial phosphatidylinositol mannosides. Biochem J. 2004; 378: p. 589-597.

28. Fukuda T, Matsumura T, Ato M, Hamasaki M, Nischiuchi Y, Marukami Y, et al. Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of mycobacteria and pathogenesis of tuberculosis. Mbio. 2013; 1(4): p. 1-11.

29. Hamasur B, Burchfeld J, Haile M, Pawlowski A, Bjorvatn B, Kallensius G, et al. Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. Journal of microbiological methods. 2001;: p. 41-52.

30. Lancioni CL, Mahan CS, Johnson DF, Walusimbi M, Chervenak KA, Nalukwago S, et al. Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4 350 cells/mm3. The journal of infectious diseases. 2011; 203: p. 992-1001.

31. Qvist T, Johansen IS, Pressler T, Hoiby N, Andersen AB, Katzenstein TL, et al. Urine lipoarabinomannan point-of-care testing in patient affected by pulmonary nontuberculous mycobacteria-experiences from the Danish cystic fibrosis cohort study. BMC infectious diseases. 2014; 14: p. 655.

32. Adam J, Caulfield, Nancy L, Wengenack. Diagnosis of active tuberculosis disease: from microscopy to molecular techniques. Journal of clinical tuberculosis and other mycobacterial disease. 2016 May.

33. Lawn SD, Wood R. Tuberculosis in HIV. Section 5 HIV and AIDS: Clinical

Presentation. 2013;: p. 865-873.

34. Pai M, OBrien R. New diagnostic for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med. 2008; 29: p. 560-568.

35. Reither K, Saathoff E, Jung J, Minja LT, Kroidl I, Saad E, et al. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC infectious diseases. 2009; 9(141): p. 1-10.

36. Mutetwa R, Boehme C, Dimairo M, Bandason T, Munyati SS, Mangwanya D. Diagnostic accuracy of commercial urinary lipo-arabinomannan detection in African TB suspects and patients. Int J Tuberc Lung Dis. 2009; 13(10): p. 1253-1259.

37. Shu CC, Wang JY, Lee LN, Yu CJ, Luh KT. Improving tuberculosis diagnostics with biomarkers. Current Biomarker Finding. 2015 May 7; 5: p. 13-19.

38. Tessema TA, Hamasur B, Bjun G, Svenson S, Bjorvatn B. Diagnostic evaluation of urinary lipoarabinomannan at an Ethiopian tuberculosis centre. Scand J Infect Dis. 2001; 33: p. 279-284.

39. Hanifa Y, Telisinghe L, Fielding KL, Malden JL, Churchyard GJ, Grant AD, Charalambous S. The diagnostic accuracy of urine lipoarabinomannan test for tuberculosis screening in a South African correctional facility. PLOS ONE. 2015; 10(5): p. 1-5.

40. Kerkhoff AD, Wood R, Vogt M, Lawn SD. Prognostic value of a quantitative analysis of lipoarabinomannan in urine from patients with HIV-associated tuberculosis. PLOS ONE. 2014; 9(7).

41. Saiga H, Shimada Y, Takeda K. Innate immune effectors in mycobacterial infection. Clinical and developmental immunology. 2011;: p. 8.

42. Lawn SD, Dheda K, Kerkhoff AD, Peter JG, Dorman S, Boehme CC, et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC infectious diseases. 2013; 13(407): p. 2-9.

43. Delogu G, Sali M, Fadda G. The biology of mycobacterium tuberculosis

infection. Mediterr J Hematol Infect Dis. 2013; 5: p. 1-8.

44. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur respir j. 2011; 38: p. 1398-1405.

45. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC infectious diseases. 2012; 12: p. 103.

46. Cox JA, Lukande, Sam Kalungi RL, Marck EV, Van de Vijver K, Kambugu A, et al. Is urinary lipoarabinomannan the result of renal tuberculosis? assesment of the renal histology in an autopsy cohort of Ugandan HIV-infected adults. PLOS ONE. 2015; 10(4): p. 1-13.

47. Lawn SD, Wright GA. Detection of lipoarabinomannan (LAM) urin is indicative of disseminated TB with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications. trans R Sac Trp Med Hyg. 2016 Nov 2; 110: p. 180-185.

48. Briken V, Porcelli SA, Besra GS, Kremer L. Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Molecular microbiology. 2004; 53(2): p. 391-403.

49. Pitarque S, Maumus, Payre B, Jackson M, Puzo G, Nigou J. The immunomodulatory lipoglycans, lipoarabinomannan and lipomannan, are exposed at the mycobacterial cell surface. Tuberculosis (Edinb). 2008; 88(6): p. 560-565.

50. World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. WHO Library Cataloguing in Publication Data. 2015;: p. 1-62.

51. Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, etal. Effect on mortality of point of care , urine based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV positive hospital inpatients: a pragmatic, parallel group, multicountry, open label, randomised controlled trial. 2016 March 9;: p. 1-11.

52. Savolainen LE. Characterization of diagnostic biomarkers for mycobacterium

tuberculosis infection. Academic Dissertation. 2014 December 12;: p. 1-80.

53. Agha MA, El-Helbawy RH, El-Helbawy NG, El-Sheak NM. Utility of quantitative analysis of urien lipoarabinomannan in the diagnosis of tuberculosis. Egyptian Journal of Chest Disease and Tuberculosis. 2013 April 30; 62: p. 401-407.

54. Patel VB, Singh R, Connolly C, Kasprowicz V, Zumla A, Ndungu T, etal. Comparison of a clinical prediction rule and a LAM antigen detection assay for the rapid diagnosis of TBM in a high HIV prevaalence setting. Open access plos one. 2010 September 30; 5(12): p. 1-9.

55. Lawn SD, Dheda K, Kerkhoff AD, Peter JG, Dorman S, Boehme CC. Determine TB-LAM lateral flow urine antigen assay for HIV associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infectious Disease. 2013 July 11; 13(407): p. 1-9.

56. Lawn SD, Kerkhoff AD, Nicol MP, Meintjes G. Underestimation of the true specificity of the urine lipoarabinomannan (LAM) point of care diagnostic assay for HIV associated tuberculosis. J Acquir Immune Defic Syndr. 2015 August 1; 69(4): p. 1-4.

57. Rachmayati S, Susanti AL, Andriyoko B. Detection of mycobacterial lipoarabinomannan with a monoclonal antibody qualitative ELISA in urine of tuberculous meningitis patients. Indones Biomed J. 1016; 8(1): p. 55-60.

58. Reither K, Saathoff E, Jung j, Minja LT, Kroidl I, Saad E, etal. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC Infectious Disease. 2009 August; 9(4): p. 1-10.

59. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN. etal. Value of urine lipoarabinomannan grade and second test for optimizing clinic based screening for HIV associated pulmonary tuberculosis. J Acquir Immune Defic Syndr. 2015; 68: p. 274-280.

60. Gounder CR, Kufa T, Wada NI, Mngomezulu V, Charalambous S, Hanifa Y, etal. Diagnostic accuracy of a urine lipoarabinomannan anzyme-linked immunosorbent assay for screening ambulatory HIV infected persons for tuberculosis. J Acquir Immune Defic Syndr. 2011 April 28; 58: p. 219-223.

61. Shah M, Variava E, Holmes CB, Coppin A, Golub JE, McCallum J, etal.

Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIB prevalence setting. J Acquir Immune Defic Syndr. 2009 March 23; 52: p. 145-151.

62. Kerkhoff AD, Wood R, Vogt M, Lawn SD. Predictive value of anemia for tuberculosis in HIV-infected patients in Sub-Saharan Africa: an indication for routine microbiological investigation using new rapid assays. J Acquir Immune Defic Syndr. 2014 May; 66(1).

63. O'Brien ME, Kupka R, Msamanga GI, Saathoff E, Hunter DJ, Fawzi WW. Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr. 2005 october; 40(2).

64. Drain PK, Gounder L, Sahid F, Moosa MYS. Rapid urine LAM testing improves diagnosis of expectorated smear-negative pulmonary tuberculosis in an HIV-endemic region. Scientific Reports. 2015 September 2; 6(19992): p. 1-9.

65. Hanrahan CF, Rie AV. Diagnostic Lipoarabinomannan in urine. BMC Infect Dic. 2012; 12: p. 103.